ARS Pharmaceuticals, Inc. develops and commercializes neffy, an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis. The company’s news commonly covers U.S. commercialization, product labeling, international approvals and licensing relationships for neffy, which is marketed as EURneffy in the European Union and the United Kingdom and under a separate trade name in China.
Recurring updates also include quarterly and annual financial results, clinical and scientific presentations on intranasal epinephrine, school-access programs, manufacturing and supply responsibilities for partners, and investor conference activity. The company’s allergy-treatment focus makes regulatory decisions, product access, clinical data and commercial launch progress central themes in its public announcements.
ARS Pharmaceuticals (Nasdaq: SPRY) reported third-quarter 2026 revenue of $37.7 million, with higher neffy sales and a narrower net loss. U.S. neffy revenue reached $33.4 million versus $31.3 million a year earlier. Net loss narrowed to $35.6 million, or $0.36 per share, from $51.2 million, or $0.52 per share.
U.S. market share rose to 5% from 4%, while field-targeted accounts reached approximately 9% from 6%. Selling, general and administrative expenses fell to $43.5 million from $74.8 million. Research spending rose to $18.3 million, including a one-time intellectual-property license payment. Cash, cash equivalents and short-term investments totaled $138.4 million at September 30. ARS reaffirmed its expectation of cash flow breakeven by year-end 2027 under its current expense plan. Interim Phase 2b data for ARS-2 are expected in the first quarter of 2027, with full data later that year.
ARS Pharmaceuticals (SPRY) will host a conference call and webcast on November 5, 2026, to review third-quarter 2026 financial results. The call begins at 1:30 p.m. PT / 4:30 p.m. ET. The webcast and slides will be accessible through the company’s Events & Presentations webpage, with a replay available for 30 days following the event.
ARS Pharmaceuticals (Nasdaq: SPRY) announced that President and CEO Donn Casale will attend two September 2026 investor events: the Wells Fargo Healthcare Conference for 1x1 meetings on September 9 in Boston, and the Cantor Global Healthcare Conference, including a fireside chat on September 11 and 1x1 meetings September 10 in New York. A live and archived webcast of the Cantor fireside chat will be available for 30 days on the company’s website.
ARS Pharmaceuticals (Nasdaq: SPRY) reported Q2 2026 total revenue of $33.7 million, including $26.2 million in U.S. neffy net product revenue, and a net loss of $62.3 million ($0.63 per share). neffy reached 5% total U.S. epinephrine market share for Type 1 allergies and 8% share in field‑targeted accounts, with over 16,000 unique prescribers.
The company realigned commercial spending toward targeted high‑volume prescribers, expects more than 40% reduction in cash‑based SG&A in 2H 2026, and guides 2H 2026 cash SG&A+R&D to $100–110 million, supporting an anticipated path to cash flow breakeven by end of 2027. Cash, cash equivalents and short‑term investments were $143.8 million on June 30, 2026. ARS Pharma also appointed Meg Smith as Chief Commercial Officer and completed expansion of its U.S. field sales force.
Beyond neffy, Phase 2b trial enrollment for CSU program ARS‑2 is underway, with interim data expected in Q1 2027.
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. President and CEO Donn Casale will outline updated strategic priorities and report second quarter 2026 financial results. Dial-in details require event registration, while webcast access and slides will be available via the company’s website, with a replay accessible for 30 days.
ARS Pharmaceuticals (Nasdaq: SPRY) announced a CEO succession. Co‑founder and CEO Richard Lowenthal ceased serving as an employee and officer on July 6, 2026. Donn Casale, previously President, became CEO and Director effective July 7, 2026.
Casale brings 25+ years of commercial leadership, including helping scale HEPLISAV-B® to over $300 million in annualized revenue and more than 50% U.S. market share prior to Sanofi’s $2.2 billion acquisition of Dynavax.
ARS Pharmaceuticals (Nasdaq: SPRY) reported no new commercial formulary additions or coverage decisions for neffy in the July 1, 2026 cycle, while payer talks continue. The company cut 2026 cash-based operating expenses (ex-COGS) to about $248 million, reaffirmed a 2027 cash-flow breakeven path, and expects Phase 2b CSU interim data in Q4 2026. Florida added neffy to its unrestricted Medicaid formulary effective July 1, 2026.
ARS Pharmaceuticals (Nasdaq: SPRY) announced a collaboration with former NFL quarterback and 2026 Hall of Fame inductee Drew Brees to raise awareness about severe food allergies and preparedness.
The effort highlights the importance of epinephrine and treatment options such as neffy, an FDA-approved epinephrine nasal spray for emergency treatment of allergic reactions, including anaphylaxis, in adults and children weighing at least 33 pounds.
ARS Pharmaceuticals (Nasdaq: SPRY) reported Q1 2026 revenue of $22.7 million, including $17.5 million in neffy U.S. net product revenue. Net loss was $60.6 million, with $201.0 million in cash and investments.
Updates included neffy label expansion, Health Canada and EU approvals, broader U.S. access initiatives, sales force expansion to 148 representatives, and progress in the Phase 2b chronic spontaneous urticaria trial, with interim data expected in Q4 2026.
ARS Pharmaceuticals (Nasdaq: SPRY) appointed industry veteran Donn Casale as President, effective June 1, 2026, while Richard Lowenthal remains CEO.
Casale will lead global commercial operations for neffy (epinephrine nasal spray) and support expansion into chronic spontaneous urticaria, drawing on prior experience scaling HEPLISAV-B to over $300 million annualized revenue.